GR-MD-02

New data regarding the mechanism of action of belapectin to inhibit galectin-3Unique pharmacokinetic profile of belapectin in patients with hepatic insufficiencyInnovating in Liver Cirrhosis: Belapectin’s NAVIGATE phase 2b/3 study…

NORCROSS, Ga., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has entered into a $20 million convertible debt…

Belapectin and KEYTRUDA® combination immunotherapy in patients with treatment-refractory and progressive diseases shows a cancer control rate of 56% in melanoma and of 40% in head and neck cancerMelanoma patients in the study had a…